



ELSEVIER

Contents lists available at ScienceDirect

Journal of Ethnopharmacology

journal homepage: [www.elsevier.com/locate/jep](http://www.elsevier.com/locate/jep)

Research Paper

## Safety and antidiarrheal activity of *Priva adhaerens* aqueous leaf extract in a murine model

Miriam Nansunga<sup>a</sup>, Ambrose Barasa<sup>a</sup>, Justus Abimana<sup>b</sup>, Paul E. Alele<sup>c,\*</sup>, Josephine Kasolo<sup>d</sup>

<sup>a</sup> Department of Physiology, Kampala International University, P.O. Box 71, Bushenyi, Ishaka, Uganda

<sup>b</sup> Department of Microbiology, Kampala International University, P.O. Box 71, Bushenyi, Ishaka, Uganda

<sup>c</sup> Department of Pharmacology and Therapeutics, Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda

<sup>d</sup> Department of Physiology, Makerere University College of Health Sciences, P.O. Box 7072, Kampala, Uganda

### ARTICLE INFO

#### Article history:

Received 9 May 2014

Received in revised form

23 September 2014

Accepted 28 September 2014

#### Keywords:

Acute toxicity

Antidiarrheal

*Priva adhaerens*

Murine model

### ABSTRACT

**Ethnopharmacological relevance:** *Priva adhaerens* (Forssk.) Chiov., a wildy growing plant, is reported in central Uganda to be an effective traditional remedy for diarrhea. The objective of this study was to provide a scientific basis for the ethnopharmacological utility of this plant whose aqueous leaf and shoot extract was evaluated for acute toxicity and antidiarrheal activity using a murine model.

**Materials and methods:** Acute toxicity of the aqueous leaf and shoot extract was assessed after determining the major phytochemicals present in the extract. The aqueous leaf and shoot extract was assayed against castor oil-induced diarrhea, transit time, and enteropooling, in comparison to loperamide, a standard drug.

**Results:** The oral LD<sub>50</sub> value obtained for *Priva adhaerens* aqueous extract was greater than 5000 mg/kg in rats; the aqueous leaf and shoot extract possessed several important phytochemicals. Furthermore, the aqueous extract significantly, and dose-dependently, reduced frequency of stooling in castor oil-induced diarrhea, intestinal motility, and castor oil-induced enteropooling in rats.

**Conclusion:** This murine model shows that it is relatively safe to orally use the aqueous leaf and shoot extract of *Priva adhaerens*. The aqueous extract contains phytochemicals that are active for the treatment of diarrhea in a rat model.

© 2014 Published by Elsevier Ireland Ltd.

### 1. Introduction

Diarrhea, the passing of increased amounts (more than 300 g in 24 h) of loose feces, and often caused by viruses or bacteria, can be acute or chronic. Etiological factors for diarrhea include the consumption of drinking water contaminated with bacteria, undercooked meat and eggs, or inadequate kitchen hygiene (Tumwine et al., 2002). Diarrhea can also be caused by food intolerance, food poisoning or as a side effect of certain medications. The World Health Organization (WHO) estimates that food-borne and water-borne diarrheal diseases taken together kill about 2.2 million people annually, 1.9 million of whom are children (United Nations Children's Fund/WHO, 2009; Black et al., 2010).

Diarrhea is the most common gastrointestinal symptom in Human Immunodeficiency Virus (HIV) infection, affecting 90% of patients, and becomes more severe as the immune system deteriorates (Katabira, 1999; Musiime et al., 2009). Diarrhea is also one of the main causes of high mortality in developing countries

where over five million children die annually from severe diarrheal diseases (United Nations Children's Fund/WHO, 2009; Black et al., 2010), being the most common cause of morbidity and mortality among infants and children worldwide. In developing countries, diarrheal diseases account for an estimated 17.5–21% of all deaths in children under the age of 5 years, equivalent to 1.5 million deaths per year. Of all child deaths from diarrhea, 78% occur in the African and South-East Asian regions, which also are disproportionately burdened with infant and childhood HIV infections (United Nations Children's Fund/WHO, 2009).

In Uganda, about two decades ago, each child on average got six episodes of diarrhea yearly Konde (1992), with one of those episodes being severe enough to result in death. In the last decade, diarrheal disease as a cause of mortality has decreased from approximately 29.5% to 22% in children below 5 years. Similarly, deaths per 1000 live births have declined from approximately 37.2% to 11.8% in children below 5 years (W.H.O. Global Health Observatory Data Repository, 2014). Despite great advances in the management of diarrheal diseases, persistent diarrhea remains a major problem in developing countries like Uganda due to its syndromic nature (Bitarakwate et al., 2003). Treatment of diarrhea includes the administration of appropriate antibiotics where

\* Corresponding author. Tel.: +256 7735 73372; fax: +256 4854 20782.

E-mail address: [paulalele@must.ac.ug](mailto:paulalele@must.ac.ug) (P.E. Alele).

indicated, and Oral Rehydration Therapy (ORT) has been very useful in the treatment (Casburn-Jones and Farting, 2004; Forsberg et al., 2007). The World Health Organization (WHO) initiated a diarrhea control program to study traditional medicine practices and other related aspects, together with the evaluation of health education and prevention approaches to combat the problems of diarrhea (Snyder and Merson, 1982; Anokbongbo et al., 1990; Eisterberg et al., 1999; George et al., 2012).

Herbal treatment for diarrhea is a widespread practice that needs further evaluation to ascertain the usefulness of specific herbal preparations used in different communities. In Uganda, 58% of mothers are estimated to use herbal extracts to treat diarrhea (Konde et al., 1992), and many traditional healers in different parts of Uganda also use herbal extracts in the treatment of diarrheal diseases (Anokbongbo et al., 1990). One of the listed herbs used in the remedy of diarrhea is *Priva cordifolia* (Sekagya et al., 2006); *Priva adhaerens* (Forssk.) Chiov. is used as an antidiarrheal agent in many parts of central Uganda (Buganda). *Priva adhaerens* belongs to the family Verbenaceae, and is an erect annual herb, up to 1 m tall, branched, with conspicuously elongated fruiting branches. The stem is quadrangular and pubescent with hooked hairs. There is no published scientific data on the antidiarrheal activity of *Priva adhaerens*; however, as mentioned, it is listed among plants with medicinal value for the remedy of diarrhea in Uganda, and the aim of the present study, therefore, was to establish the safety and effectiveness of *Priva adhaerens* in the treatment of diarrhea in a rat model of induced diarrhea.

## 2. Materials and methods

### 2.1. Collection and authentication

Shoots and leaves of the wildy growing plant *Priva adhaerens* were collected from abandoned farmland in Mityana District, in central Uganda. A sample of the plant material was taken to the Herbarium of the Botany Department, Makerere University, Kampala, for identification. A voucher specimen has been preserved in our laboratory for further reference (voucher number 41912). The leaves obtained were shade-dried for two weeks and then ground to fine powder after which extraction was done using water.

#### 2.1.1. Extraction of plant materials

Fine powder (100 g) of air-dried leaves of *Priva adhaerens* was subjected to the Soxhlet extractor for continuous hot extraction with distilled water. The extract was filtered and the filtrate freeze-dried. As quality control, the aqueous extract was also obtained by maceration through soaking the powder overnight in distilled water, filtering in the morning, then freeze-drying the extract; the results of both methods of extraction revealed the same results for phytochemical analysis. The dried extract was then used to determine acute toxicity and antidiarrheal activity in rats. The stock dose concentration was 200 mg/ml, calculated by dissolving 2 g of the extract in 10 ml of distilled water for the dose-response studies carried out.

### 2.2. Experimental design and animals

This study was a between-groups experimental one, designed to show the difference between group means indicating the size of the effect of the treatments administered. Albino Wistar rats of either sex weighing between 150 and 200 g were used for experiments. The animals were maintained at the animal house of the Department of Pharmacology, Faculty of Veterinary Medicine, Makerere University, and were group-housed. The rats were fed with

standard animal pellets and had access to clean water ad libitum. The animals were maintained under standard conditions of humidity, temperature and 12 h light: 12 h darkness cycle. Experimental treatments and animal sample sizes involved in acute toxicity testing, castor oil-induced diarrhea, gastrointestinal motility test, and castor oil-induced enteropooling are detailed in Sections 2.4–2.7 below. The research was reviewed and approved by the Institutional Review Committee, Mbarara University (approval number, 06/09–12); and Uganda National Council for Science and Technology (approval number, HS1299), prior to its conduct. All procedures were in accordance with the approved Animal Welfare Protocols and NIH guidelines for the humane care and use of animals.

### 2.3. Preliminary phytochemical screening

Preliminary phytochemical screening for detection of various constituents was carried out using standard procedures (Harborne, 1973; Odebiyi and Sofowora, 1991; Evans, 2009). Briefly, alkaloid detection was carried out by extracting 1 g powdered sample with 5 ml methanol and 5 ml of 2 N HCL, then treating the filtrate with Mayer's and Wagner's reagents. The samples were scored positive based on turbidity or precipitation. Testing was done for flavonoids by heating 1 g powdered sample with 10 ml ethyl acetate over a steam bath (40–50 °C) for 5 min; filtrate was treated with 1 ml dilute ammonia. A yellow coloration demonstrated a positive test for flavonoids. The presence of tannins was confirmed by boiling 0.5 g powdered sample in 20 ml distilled water, followed by addition of 3 drops of 5% FeCl<sub>3</sub> to the filtrate. Development of brownish-green or blue-black coloration was taken as positive for the presence of tannins. Saponin content was determined by boiling 1 g powdered sample in 10 ml distilled water for 15 min and after cooling, the extract was shaken vigorously to record froth formation. Cardiac glycosides were identified by extracting 2 g sample in 10 ml methanol; 5 ml of this methanolic extract was treated with 2 ml glacial acetic acid containing 1 drop of 5% FeCl<sub>3</sub> solution. This solution was carefully transferred to the surface of 1 ml conc. H<sub>2</sub>SO<sub>4</sub>. The formation of a reddish-brown ring at the junction of the two liquids was indicative of cardenolides/ cardiac glycosides (Odebiyi and Sofowora, 1991; Evans, 2009). Baljet test was done to determine the presence of cardioselective glycosides (digitoxose); sodium picrate was added to a small amount of the extract and a positive test shown as a yellow to orange color. In Borntrager's test, the powdered extract was macerated with ether, and after filtration, aqueous ammonia was added. A pink, red or violet color in the aqueous layer after shaking indicates the presence of free anthraquinone derivatives; if the tested extract being tested contained either very stable anthraquinone glycosides or reduced derivatives of the anthranol type, Borntrager's test would be negative (Evans, 2009). Fehling's test was done by adding Fehling's solution drop by drop to a heated solution of the aqueous extract; the presence of a brick-red precipitate indicated the presence of a reducing sugar.

### 2.4. Acute toxicity test

Lethal effective dose on 50% of the experimental animals (LD<sub>50</sub>) following oral administration of the aqueous leaf and shoot extract of *Priva adhaerens* was estimated in Wistar albino rats (150–200 g) following Lorke's method (Lorke, 1983). Recognizing that WHO guidelines W.H.O (1998) do not require pre-clinical toxicity testing for herbal products that have been used by communities without demonstrated harm, we nonetheless wanted to ascertain the safety of the aqueous extract of *Priva adhaerens* as used in traditional medicine. Because of the ethnomedical use of this plant (diarrheal treatment), it is likely that even an acute mild or

1 moderate toxic effect could exacerbate diarrhea and potentially  
2 produce a fatal outcome, especially in young children. We chose  
3 Lorke's method which gives a more robust estimation of the  
4 median lethal dose (LD<sub>50</sub>) than the fixed-dose procedure in the  
5 OECD guideline for acute oral toxicity. Therefore, we wanted to  
6 establish a more robust value for LD<sub>50</sub>; at the same time however,  
7 we wanted to demonstrate that indeed, doses that were far less  
8 than the toxic doses studied, had antidiarrheal activity, as shown  
9 in this rat model, especially because there was no prior toxicology  
10 study on *P. adhaerens*. Undeniably, we used more animals than the  
11 OECD 420 guideline.

12 Dose levels used ranged from 5000 to 13,000 mg/kg of the  
13 aqueous extract. The 13,000 mg/kg dose was made by dissolving  
14 the dry extract of *Priva adhaerens* in a ratio of 1.3 g: 100 ml of  
15 distilled water, and then administering this in a volume not  
16 exceeding 2 ml/kg body weight of the rat. The other doses were  
17 made in a similar manner. This volume of administration followed  
18 guidelines for enteral administration, especially of aqueous solu-  
19 tions (Brown et al., 2000; Turner et al., 2011). The acute toxicity  
20 LD<sub>50</sub> was then calculated as the geometric mean of the dose that  
21 resulted in 100% lethality and that which caused no lethality at all.  
22 Toxicity signs such as death, changes in physical appearance, and  
23 behavioral changes were observed for 72 h after administration of  
24 aqueous leaf and shoot extract of *Priva adhaerens*.

### 25 2.5. Castor oil-induced diarrhea

26 The method described by Awouters et al. (1978) and Beck et al.  
27 (1977) was followed; healthy albino Wistar rats, both male and  
28 female, weighing 150–200 g were randomly selected and divided  
29 into five groups of five animals each. The rats were fasted for 18 h  
30 prior to the test, with free access to water. Rats in group 1 received  
31 20 ml/kg of normal saline (negative control), while rats in group  
32 2 received loperamide (5 mg/kg) as positive control treatment.  
33 Rats in group 3 received 100 mg/kg, rats in group 4 received  
34 200 mg/kg and rats in group 5 received 400 mg/kg *Priva adhaerens*  
35 extract. The animals were housed singly in cages lined with  
36 transparent paper. One hour later after pre-treatment with the  
37 extract, the animals were then administered 1 ml of castor oil  
38 orally. Thereafter, they were observed for 4 h for the presence of  
39 diarrhea. Diarrhea for the purpose of this study was taken to mean  
40 watery (wet), unformed stool.

### 41 2.6. Gastrointestinal motility test (charcoal meal)

42 Wistar albino rats, both male and female, weighing between  
43 150 and 200 g were randomly divided into 5 groups of 5 rats each,  
44 (Rajput et al., 2011). They were fasted for 18 h prior to test, but  
45 were allowed water ad libitum. Rats in group 1 were treated with  
46 20 ml/kg normal saline and served as control, while rats in groups  
47 2, 3, and 4 received different doses of the extract (100, 200, and  
48 400 mg/kg). Rats in group 5 received atropine sulfate (5 mg/kg).  
49 Thirty minutes after drug administration, 1 ml of charcoal meal  
50 (5% deactivated charcoal in 10% aqueous tragacanth) was adminis-  
51 tered orally to all animals in the study then after a further 30 min,  
52 all the rats were sacrificed and the abdominal cavity opened. The  
53 small intestines were dissected out from the pylorus to the cecum  
54 and the total distance travelled by the charcoal plug along the  
55 small intestine was estimated for both the control and the treated  
56 groups. The percentage distance travelled by the charcoal meal  
57 from the pylorus to the cecum was noted.

### 58 2.7. Castor oil-induced enteropooling

59 In this method (Rajput et al., 2011), rats were fasted for 18 h  
60 prior to the experiment. The rats were divided into five groups of

61 five rats per group. Normal saline (20 ml/kg orally) was given to  
62 the first group. The second group received 5 mg/kg of loperamide,  
63 while the last three groups received graded doses of *Priva*  
64 *adhaerens* extract at 100, 200 and 400 mg/kg orally, respectively.  
65 Thirty minutes later, all the rats were treated with 1 ml of castor  
66 oil. After a further 30 min, each rat was sacrificed, the abdominal  
cavity opened, and the whole length of the intestine from the  
pylorus to the cecum, was dissected and the contents measured.  
Percentage reduction of the intestinal secretion (volume) was  
calculated.

### 2.8. Data analysis

Results were expressed as mean ± SEM (standard error of the  
mean). Data were analyzed using one-way analysis of variance  
(ANOVA). In these tests, homogeneity of variances was tested  
using Bartlett's test, and differences in the means tested using  
ANOVA followed by Bonferroni multiple comparison test as the  
post-hoc test. Values of  $p < 0.05$  were considered statistically  
significant for the treatment differences. Statistical analysis was  
done using GraphPad Prism<sup>®</sup> version 6.0 (GraphPad<sup>®</sup> Software,  
Inc, La Jolla, CA, USA).

## 3. Results

### 3.1. Phytochemical screening

Phytochemical screening, by identifying the presence of che-  
micals in the extract, provides a reference for benchmarking in  
subsequent studies on the same plant. This procedural screen  
allows quality control and standardization in the event that a  
phytomedicine is developed. Screening results showed the  
presence of most of the phytochemicals in the aqueous leaf and  
shoot extracts; screening was positive for saponins, glucides and  
reducing compounds, catechol tannins, alkaloids, and cardenolides  
or steroidal glycosides. Anthraquinones (anthracenosides and  
anthrocyanosides), and flavonoids were absent in these aqueous  
extracts.

### 3.2. Acute toxicity

Following phytochemical screening, we conducted an acute  
toxicity study to estimate the median lethal dose (LD<sub>50</sub>), and to  
estimate the doses that we would use to carry out the antidiar-  
rheal testing. Signs of toxicity that were observed included  
excessive urination due to relaxation of bladder sphincter muscles  
with constriction of detrusor muscles, convulsions, defecation, GIT  
muscle twitches, and pupillary dilation; death was the end-point  
of acute toxicity. No animal died after administration of the oral  
dose of 5000 mg/kg body weight of *Priva adhaerens*; conversely, all  
animals given the oral dose of 13,000 mg/kg body weight, died  
(Table 1). These two doses allowed the oral lethal dose on 50% of  
the rats to be calculated (Fig. 1) as 8320 mg/kg body weight.

### 3.3. Antidiarrheal activity

After establishing the LD<sub>50</sub>, and the treatment doses to use, the  
next step was to do the dose-dependent assay of antidiarrheal  
activity in the rats using the aqueous extract of *Priva adhaerens*.  
We used the crude aqueous extract and not the “pure” main  
chemical compound(s) isolated from the plant extract because our  
aim was to simulate the manner in which the plant is used  
traditionally in ethnomedicine to treat diarrhea. In addition, herbal  
extracts (or phytomedicines) contain several compounds that may  
be pro-drugs, may have additive or synergistic effects with each


other, or even have different pharmacokinetic profiles. Our goal in this study therefore, was to evaluate the “whole” first, and later, in other studies perhaps, test the main compound(s) isolated, alone or in combination.

**Table 1**

Results of the lethal doses of aqueous plant extract for the determination of LD<sub>50</sub> after oral administration (n=6).

Group	Dose (mg/kg)	Log dose	Number dead	% dead	Probits
1	5000	3.69	0/6	0	3.45
2	7000	3.85	1/6	16.67	4.19
3	9000	3.95	3/6	50	5.15
4	11,000	4.04	4/6	66.67	5.56
5	13,000	4.11	6/6	100	6.96

No animal died after administration of the oral dose of 5000 mg/kg body weight of *Priva adhaerens*; conversely, all animals given the oral dose of 13,000 mg/kg body weight, died; the intermediate dose of 7000 mg/kg caused the death of 1 of 6 animals, the 9000 mg/kg dose caused the death of 3 of 6 animals, and the 11,000 mg/kg dose caused the death of 4 of 6 animals; n=6.



**Fig. 1.** Graph of log dose vs. probits to determine the LD<sub>50</sub> of the aqueous extract. LD<sub>50</sub> calculation was done using the formula  $Y = 7.851X - 25.77$ . Whereas  $y = 5$ ,  $5 = 7.851X - 25.77$ ,  $X = 5 + 25.77/7.852$ ,  $X = 3.92$ , LD<sub>50</sub> = Antilog of 3.92. LD<sub>50</sub> = 8317.64 mg/kg body weight. Therefore, the LD<sub>50</sub> of *Priva adhaerens* aqueous leaf extract was estimated to be 8320 mg/kg of body weight.

**Table 2**

Effect of aqueous extract of *Priva adhaerens* on castor oil-induced diarrhea assayed as the number of wet feces in 5 h wet fecal weight in Wistar albino rats, gastrointestinal (GIT) transit time (distance traveled by charcoal), and volume of intestinal contents (enteropooling).

Treatment groups	Dose	Number of wet feces in 5 h	95 % CI of difference	Weight of wet fecal matter (g)	95 % CI of difference	Distance traveled by charcoal (mm)	95 % CI of difference	Volume of intestinal contents (ml)	Volume of intestinal contents (ml)
Positive control	20 ml/kg	3.32 ± 0.30	2.485 to 4.155	4.07 ± 1.27	0.02 to 8.12	68.20 ± 2.59	60.99 to 75.41	2.38 ± 0.21	1.71 to 3.04
Positive control	Diverse (see text)	120 ± 0.29*	0.376 to 2.024	1.94 ± 0.53	0.24 to 3.63	24.20 ± 2.52**	17.21 to 31.19	0.45 ± 0.04*	0.34 to 0.57
Group 1 extract	100 mg/kg	2.16 ± 0.37	1.130 to 3.190	3.45 ± 1.20	-0.36 to 7.26	60.60 ± 1.778 <sup>a</sup>	55.66 to 65.54	1.08 ± 0.11*, **	0.78 to 1.38
Group 2 extract	200 mg/kg	1.36 ± 0.37*	0.330 to 2.390	2.55 ± 0.80	0.001 to 5.10	54.40 ± 1.50*** <sup>a</sup>	50.23 to 58.57	0.78 ± 0.05*	0.64 to 0.93
Group 3 extract	400 mg/kg	0.96 ± 0.28*	0.187 to 1.733	1.94 ± 0.62	-0.04 to 3.90	37.60 ± 3.23*** <sup>a,b,c</sup>	28.62 to 46.58	0.52 ± 0.04*, ***	0.40 to 0.64

*Priva adhaerens* aqueous extract significantly reduced the number of wet feces in 5 h compared to the negative control group. Values shown for number of wet feces in 5 h are mean ± SEM; \*p < 0.05, comparing negative control group with loperamide (positive control) group, with group 2 extract, and with group 3 extract; n=6. After induction of diarrhea by castor oil, there was no statistically significant difference between the treatment groups for weight of wet fecal matter (columns 5 and 6). Values shown for weight of fecal matter are means ± SEM. *Priva adhaerens* aqueous extracts also significantly reduced the distance traveled by charcoal in a dose-dependent manner, with the 200 mg/kg and the 400 mg/kg doses showing increasing efficacy (columns 7 and 8). As expected, atropine sulfate (the positive control) showed the best efficacy in reducing the distance traveled by charcoal, compared to all the groups. Values shown for distance traveled by charcoal are mean ± SEM; \*\*p < 0.05, comparing negative control with atropine sulfate (positive control) group; \*\*\*p < 0.05, comparing negative control with group 2 and with group 3 extracts;

<sup>a</sup> p < 0.05, comparing positive control with extracts from groups 1, 2, and 3;

<sup>b</sup> p < 0.05, comparing group 1 extract with group 3 extract;

<sup>c</sup> p < 0.05, comparing group 2 extract with group 3 extract; n=6. Lastly, *Priva adhaerens* aqueous extracts significantly reduced the volume of intestinal contents (enteropooling) in a dose-dependent manner compared to negative control (columns 9 and 10). Values shown for volume of intestinal contents are mean ± SEM;

\* p < 0.05, comparing negative control with loperamide (positive control) group, with group 1, with group 2, and with group 3 extracts;


\*\* p < 0.05, comparing positive control with group 1 extract;

\*\*\* p < 0.05, comparing group 1 extract with group 3 extract; n=6.


Treatment of the rats produced a significant difference in the effect of treatment on castor oil-induced diarrhea [ $F_{(4, 29)} = 8.786$ ,  $p < 0.0001$ ]. The aqueous extracts of *Priva adhaerens* at 200 mg/kg and 400 mg/kg body weight significantly reduced the number of wet feces in five hours, compared to negative control animals (Table 2). There was no statistical difference between the loperamide (positive control) group and the extract-treated groups, implying that the extracts produced similar effect as the loperamide positive control (Fig. 2 and Table 2).

Treatment of the rats did not produce any significant difference in the effect of treatment on castor oil-induced diarrhea by wet fecal weight (Fig. 3 and Table 2).

On gastrointestinal transit time in the rats, measured by the distance traveled by charcoal, treatment of the rats produced a



**Fig. 2.** Antidiarrheal activity of the aqueous extract of *Priva adhaerens* in castor oil-induced diarrhea. *Priva adhaerens* aqueous extract significantly reduced the number of wet feces in 5 h compared to the negative control group. Values shown for number of wet feces are mean ± SEM; \*p < 0.05, comparing negative control group with loperamide (positive control) group, with group 2 extract, and with group 3 extract; n=6.



**Fig. 3.** Weight of wet fecal matter (gm). Values shown for weight of fecal matter are means  $\pm$  SEM; there was no statistically significant difference between the treatment groups for weight of wet fecal matter after induction of diarrhea by castor oil.

significant difference in the effect of treatment on distance traveled by charcoal [ $F_{(4, 29)}=55.23, p < 0.0001$ ] (Table 2). The aqueous extracts of *Priva adhaerens* significantly reduced the distance traveled by charcoal in a dose-dependent manner, with the 200 mg/kg and the 400 mg/kg doses studied showing the greatest reduction in gastrointestinal motility compared to the negative control group.

Lastly, treatment of the rats produced a significant difference in the effect of treatment on castor oil-induced enteropooling [ $F_{(4, 29)}=50.15, p < 0.0001$ ]. *Priva adhaerens* aqueous extracts significantly reduced the volume of intestinal contents (enteropooling) in a dose-dependent manner compared to negative control (Table 2).

#### 4. Discussion

The present study sought to assess the safety and antidiarrheal activity of the aqueous extract of *Priva adhaerens* leaves and shoots. Diarrhea results from an imbalance between the absorptive and secretory mechanisms in the intestinal tract, accompanied by an excess loss of fluid in feces. Field surveys done about 25 years ago showed that more than half of traditional healers in five districts representing different regions of Uganda used herbal medicines with water as the main vehicle (Anokbonggo et al., 1990). *Priva adhaerens* is one of the herbs still used traditionally in Uganda in managing diarrhea, especially in central Uganda (Buganda region). In some types of diarrhea, the secretory component predominates, while other types of diarrhea are characterized by hypermotility. The aqueous leaf extract of *Priva adhaerens* did not show any toxic effects at the dose of 5000 mg/kg; this dose did not alter the behavior of normal animals, nor did it cause any deaths in this group of animals. Generally, substances that are not toxic at 5000 mg/kg, are considered relatively safe (Lorke, 1983). *Priva adhaerens* aqueous extract was considered, therefore, to be safe at doses  $\leq$  5000 mg/kg. Our findings also showed that the extract inhibited castor oil-induced diarrhea in rats significantly, comparing the inhibition favorably with that of the standard antidiarrheal drug loperamide.

It has been observed that the most active component of castor oil, ricinoleic acid produces an irritating action on the intestinal mucosa, that stimulates peristaltic activity of the small intestines (Rouf et al., 2003; Rouf et al., 2007). The irritation causes changes in the permeability of the intestinal mucosa to electrolytes. Castor

oil is also believed to cause release of prostaglandins, which stimulate motility and secretion, thereby decreasing the absorption of sodium and potassium ions (Zavala et al., 1998); Rouf et al., 2003). The aqueous extract of *Priva adhaerens* significantly reduced the intestinal transit, as was observed by a decrease in the intestinal motility of the charcoal meal. This also compared well with the antimuscarinic drug atropine, and different doses decreased the propulsive movements in the charcoal meal.

The aqueous extract of *Priva adhaerens* also significantly reduced intestinal fluid accumulation (enteropooling) as was observed by the reduced volume of intestinal contents, which compared favorably with loperamide. This effect suggests the usefulness of this extract in the management of diarrhea. The inhibition of castor oil-induced enteropooling, may be due to the ability of the extract to increase reabsorption of the electrolytes and water, also observed with the standard drug loperamide. It can also be assumed that the antidiarrheal action of the extract was mediated by an antisecretory mechanism.

Secretory diarrhea is associated with an activation of chloride ( $\text{Cl}^-$ ) channels causing  $\text{Cl}^-$  ion efflux from the cell; the efflux of  $\text{Cl}^-$  results in massive secretion of water into the intestinal lumen and profuse watery diarrhea Ammon and Soergel (1985). The extract might inhibit the secretion of water into the lumen by reversing this mechanism. Loperamide regulates the gastrointestinal tract by inhibiting the propulsive activities, predominantly in the jejunum. Other effects on intestinal motility may be mediated through inhibition of prostaglandin stimulation of gut motility and/or through calcium antagonist actions (W.H.O., 1990). Apart from regulating the gastrointestinal tract, loperamide is also reported to reduce colonic flow, and consequently increase colonic water absorption, but does not have any effect on colonic motility. Because of the similarity in the effects of loperamide and the dose-dependent decrease in wet fecal matter, as well as the dose-dependent reduction in castor oil-induced enteropooling, it is possible that the aqueous leaf extract of *Priva adhaerens* could have the same mechanism of action as loperamide.

Phytochemical analysis of the extract of *Priva adhaerens* showed the presence of saponins, mucilages, reducing compounds, glucides, tannins, alkaloids, and steroidal glycosides, which have been reported to be present in other plants with antidiarrheal properties (William et al., 2009). It is possible that the bioactive compounds in the leaf extract of *Priva adhaerens* are responsible for the antidiarrheal effects recorded for the extract. Earlier studies have shown that anti-diarrheal properties of medicinal plants were found to be due to tannins, alkaloids, saponins, flavonoids and reducing sugars (Longanga et al., 2000). Tannins, saponins, and alkaloids in the extract, may be responsible for the antidiarrheal activity of the *Priva adhaerens* extract. One of the limitations of our study was that we did not perform histology of the organs after termination of the study. However, we predicted that since diarrhea is usually treated acutely, and since the doses we used in our study were several times lower than the  $\text{LD}_{50}$ , histological examination would be more relevant for a chronic or long-term study of *Priva adhaerens*.

In conclusion, *Priva adhaerens* is generally safe for acute use at moderate doses, and exhibits antidiarrheal activity. The dose-related antidiarrheal activity shown by the aqueous extract of *Priva adhaerens* leaves suggests the presence of some active phytochemicals, which act through one or more antidiarrheal mechanisms. The possible clinical significance of these findings therefore, is that this murine model has established the acute safety of *Priva adhaerens*, at least in rats, and has established that the aqueous leaf extract possesses antidiarrheal activity. Controlled clinical trials of *Priva adhaerens* to establish its safety and efficacy are warranted to develop recommendations further justifying its use in traditional medicine, but long-term pre-clinical

1 toxicity should be investigated, as should its mechanism of  
 2 antidiarrheal activity.

### 4 References

- 5  
 6 Ammon, H.V., Soergel, K.L., 1985. Diarrhea. In: Berk, J.E. (Ed.), Gastroenterology. Saunders, Philadelphia, pp. 125–140.
- 7 Anokbonggo, W.W., Odoi-Adome, R., Oluju, P.M., 1990. Traditional methods in management of diarrhoeal diseases in Uganda. Bulletin of the World Health Organisation 68 (3), 359–363.
- 8 Awouters, F., Nimegeers, C.J.E., Lenaerts, F.M., Janssen, P.A.J., 1978. Delay of castor oil diarrhoea in rats: a new way to evaluate inhibitors of prostaglandins biosynthesis. Journal of Pharmacy and Pharmacology 30, 41–45.
- 9 Beck, I.T., Jenkins, N., Thurber, L., Ambrus, J.L., 1977. Methods for the study of antidiarrheal agents. Study of commonly used protective and adsorbent agents. Journal of Medicine 8 (2), 135–158.
- 10 Bitarakwate, E., Mworozzi, E., Kekitiinwa, A., 2003. Serum zinc status of children with persistent diarrhoea admitted to the diarrhoea management unit of Mulago hospital, Uganda. African Health Sciences 3 (2), 54–60.
- 11 Black, S.E., Cousens, S., Johnson, H.L., Lawn, J.E., Rudan, I., et al., 2010. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375 (9730), 1969–1987.
- 12 Brown, A.P., Dinger, N., Levine, B.S., 2000. Stress produced by gavage administration in the rat. Contemporary Topics in Laboratory Animal Science 39 (1), 17–21.
- 13 Casburn-Jones, A.C., Farting, M.J.G., 2004. Management of infectious diarrhoea. International Journal of Gastroenterology and Hepatology 23 (2), 296–305.
- 14 Eisterberg, D., Davis, R., Eitfer, S., 1999. Trends in alternative medicine use in the United States 1990–1997 results of a follow up survey. Journal of American Medical Association 288, 1569–1575.
- 15 Evans, W.C., 2009. In: Graham, P., Urquhat, J. (Eds.), Pharmacognosy, 16th ed. Saunders Elsevier, Philadelphia.
- 16 Forsberg, B.C., Petzold, M.G., Allebeck, P., 2007. Diarrhoea case management in low- and middle-income countries – an unfinished agenda. Bulletin of the World Health Organisation 85 (06), 42–48.
- 17 George A., Young M., Nefdt R., Basu R., Sylla M., Bannicq M.Y., and Diaz T. (2012). Community case management of childhood diarrhoea, malaria and pneumonia: Tracking science to policy and practice in sub-Saharan Africa.
- 18 Harborne, J.B., 1973. Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis. Chapman & Hall, London 279.
- 19 Katabira, E.T., 1999. Epidemiology and management of diarrheal diseases in HIV infected patient. International Journal of Infectious Disease 3 (3), 164–167.
- 20 Konde, J.K., Lule, Elasu, S., Musonge, D.L., 1992. Knowledge, attitudes and practices. Their policy implications in childhood diarrhoea in Uganda. Journal of Diarrheal Disease Research 10 (1), 25–30.
- 21 Longanga, O.A., Verduyck, A., Foriers, A., 2000. Contribution to the ethnobotanical, phytochemical and pharmacological studies of traditionally used medicinal plants in the treatment of dysentery and diarrhoea in Lomela area, Democratic Republic of Congo. Journal of Ethnopharmacology 71 (3), 411–423.
- 22 Lorke, D., 1983. A new approach to acute toxicity testing. Archives of Toxicology 54, 275–287.
- 23 Musiime, V., Kalyesubula, I., Mulindwa, K., Byarugaba, D.J., 2009. Enteric bacterial pathogens in HIV-infected children with acute diarrhoea in Mulago referral and teaching Hospital. International Association of Physicians in AIDS Care 8 (3), 185–190.
- 24 Odebiyi, O.O., Sofowora, E.A., 1991. Phytochemical screening of Nigerian medicinal plants II. (The Journal of Natural Products). Lloydia 41 (3), 234–246.
- 25 Rajput, M.S., Nuir, V., Akansha, C., Jawanjali, H., Dange, V., 2011. Evaluation of antidiarrheal activity of aerial parts of *Vinca major* in experimental animals. Middle-East Journal of Scientific Research 7 (5), 784–788.
- 26 Rouf, A.S.S., Islam, M.S., Rahman, M.T., 2003. Evaluation of antidiarrhoeal activity of *Rumex maritimus* root. Journal of Ethnopharmacology 84, 2001–2004.
- 27 Rouf, R., Uddin, S.J., Shilpi, J.A., Alamgir, M., 2007. Assessment of antidiarrhoeal activity of the methanol extract of *Xylocarpus granatum* bark in mice model. Journal of Ethnopharmacology 109, 539–542.
- 28 Sekagya Y.H., Finch L., Garanganga E. (2006). Traditional medicine. In A Clinical Guide to Supportive and Palliative Care for HIV/AIDS in Sub-Saharan Africa.
- 29 Snyder, J.D., Merson, M.H., 1982. The magnitude of the global problem of acute diarrhoeal disease: a review of active surveillance data. Bulletin of the World Health Organization 60 (4), 605–613.
- 30 Tumwine, J.K., Thompson, J., Katua-Katua, M., Mujwajuzi, M., Porrart, J.N., 2002. Diarrhoea and effects of different water sources, sanitation and hygiene behaviour in East Africa. Tropical Medicine and International Health 7 (9), 750–756.
- 31 Turner, P.V., Brabb, T., Pekow, C., Vasbinder, M.A., 2011. Administration of substances to laboratory animals: routes of administration and factors to consider. Journal of the American Association for Laboratory Animal Science 50 (5), 600–613.
- 32 United Nations Children's Fund/WHO. 2009. *Diarrhoea: Why children are still dying and what can be done*. Geneva.
- 33 W.H.O.. Global Health Observatory Data Repository 2014 Available from (<http://apps.who.int/gho/data/view.main.ghe200-UGA>) accessed (20.9.14.).
- 34 W.H.O.1998.Guidelines for the Appropriate Use of Herbal Medicines. Manila: W.H.O. Regional Office for the Western Pacific.
- 35 W.H.O.Programme for the Control of Diarrheal Diseases.1990. The Rationale Use of Drugs in the Management of Acute Diarrhoea in Children (Vol. 17). Geneva: W.H.O.
- 36 William, E.T., Barminas, J.T., Aknniyi, J., William, A., 2009. Antidiarrheal effects of the root extracts of *Guiera senegalensis* in male mice. African Journal of Pure and Applied Chemistry 3 (8), 152–157.
- 37 Zavala, M.A., Perez, S., Perez, C., Vargas, R., Perez, R.M., 1998. Antidiarrhoeal activity of *Waltheria americana*, *Commelina coelestis* and *Alternanthera repens*. Journal of Ethnopharmacology 61, 41–47.